Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method

Download
  1. Get@NRC: Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1021/mp3004995
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titleMolecular Pharmaceutics
ISSN1543-8384
Volume10
Issue5
Pages15421556; # of pages: 15
SubjectFC44 antibody; FC5 antibody; nanobody; peptides and proteins; unclassified drug; animal cell; animal experiment; animal tissue; article; binding affinity; blood brain barrier; blood cerebrospinal fluid barrier; brain cell; brain endothelial cell; cerebrospinal fluid; controlled study; drug cerebrospinal fluid level; endothelium cell; fluorescence imaging; human; human cell; in vitro study; isotope labeling; limit of detection; limit of quantitation; male; microvascular endothelial cell; molecular weight; nonhuman; nucleotide sequence; outcome assessment; phage display; plasma half life; priority journal; treatment duration
AbstractFC5 and FC44 are single-domain antibodies (VHHs), selected by functional panning of phage-display llama VHH library for their ability to internalize human brain endothelial cells (BEC) and to transmigrate the in vitro BBB model. Quantification of brain delivery of FC5 and FC44 in vivo was challenging using classical methods because of their short plasma half-life and their loss of functionality with radioactive labeling. A highly sensitive (detection limit <2 ng/mL) and specific SRM-ILIS method to detect and quantify unlabeled VHHs in multiplexed assays was developed and applied to comparatively evaluate brain delivery of FC5 and FC44, and two control VHHs, EG2 and A20.1. FC5 and FC44 compared to control V HHs demonstrated significantly (p < 0.01) enhanced transport (50-100-fold) across rat in vitro BBB model as well as in vivo brain targeting assessed by optical imaging. The multiplexed SRM-ILIS analyses of plasma and CSF levels of codosed VHHs demonstrated that while all 4 VHHs have similar blood pharmacokinetics, only FC5 and FC44 show elevated CSF levels, suggesting that they are potential novel carriers for delivery of drugs and macromolecules across the BBB. © Published 2012 by the American Chemical Society.
Publication date
LanguageEnglish
AffiliationNational Research Council Canada (NRC-CNRC); Human Health Therapeutics (HHT-TSH)
Peer reviewedYes
NPARC number21269642
Export citationExport as RIS
Report a correctionReport a correction
Record identifier0d951595-1ff4-4447-965c-44d5a9dc3e9c
Record created2013-12-13
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)